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Baseline Characteristics of the Korean Registry of Pulmonary 
Arterial Hypertension 
Despite recent advances in understanding of the pathobiology and targeted treatments of 
pulmonary arterial hypertension (PAH), epidemiologic data from large populations have 
been limited to western countries. The aim of the Korean Registry of Pulmonary Arterial 
Hypertension (KORPAH) was to examine the epidemiology and prognosis of Korean 
patients with PAH. KORPAH was designed as a nationwide, multicenter, prospective data 
collection using an internet webserver from September 2008 to December 2011. A total of 
625 patients were enrolled. The patients’ mean age was 47.6 ± 15.7 yr, and 503 (80.5%) 
were women. The diagnostic methods included right heart catheterization (n = 249, 
39.8%) and Doppler echocardiography (n = 376, 60.2%). The etiologies, in order of 
frequency, were connective tissue disease (CTD), congenital heart disease, and idiopathic 
PAH (IPAH) (49.8%, 25.4%, and 23.2%, respectively). Patients with WHO functional class 
III or IV at diagnosis were 43.4%. In total, 380 (60.8%) patients received a single PAH-
specific treatment at the time of enrollment, but only 72 (18.9%) patients received 
combination therapy. Incident cases during the registry represented 297 patients; 
therefore, the incidence rate of PAH was 1.9 patients/yr/million people. The 1st-, 2nd-, 
and 3rd-yr estimated survival rates were 90.8%, 87.8%, and 84.4%, respectively. 
Although Korean PAH patients exhibited similar age, gender, and survival rate compared 
with western registries, they showed relatively more CTD-PAH in the etiology and also 
systemic lupus erythematosus among CTD-PAH. The data suggest that earlier diagnosis and 
more specialized therapies should be needed to improve the survival of PAH patients.
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INTRODUCTION 
Pulmonary arterial hypertension (PAH) is characterized by remodeling of the small 
pulmonary arteries leading to a progressive increase in pulmonary vascular resistance 
(PVR), right ventricular failure and death (1-4). The diagnosis and management of PAH 
has undergone significant change since the National Institutes of Health (NIH) con-
ducted the first registry of primary pulmonary hypertension in the early 1980s (5, 6). 
According to the last update at the 5th World Symposium on Pulmonary Hypertension, 
PAH, or group 1 pulmonary hypertension (PH), includes idiopathic PH, inherited PH, 
and PH associated with other conditions or diseases, such as connective tissue disease, 
congenital heart disease, portal hypertension, HIV infection, and exposure to toxins 
and drugs (7). Even with increased physician awareness and the relatively recent ther-
apeutic developments, PAH remains an incurable and eventually fatal disease.
 From 2006 to 2007, the Registry to EValuate Early And Long-term PAH disease man-
agement (REVEAL) study in the United States provided us with important basic data 
on the epidemiology, clinical characteristics, and prognosis of PAH (8-10). However, it 
is not known whether the results of these studies can be extended to different races, 
such as East Asian. The Korean Registry of Pulmonary Arterial Hypertension (KORPAH) 
was initiated to obtain additional insight into the incidence, prevalence, epidemiology, 
therapeutic modalities and survival data of Korean patients with PAH.
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MATERIALS AND METHODS
Patients
This registry was designed as a multicenter, prospective data 
collection center using a common internet webserver. In Janu-
ary 2008, a task force team was formulated from 4 academic so-
cieties in Korea (The Korean Academy of Tuberculosis and Re-
spiratory Diseases, The Korean Society of Cardiology, Korean 
College of Rheumatology, and The Korean Pediatric Heart So-
ciety) to create a common diagnostic protocol and webserver 
for the registry. Thirty-five university hospitals and tertiary hos-
pitals in South Korea participated in this registry. When a pa-
tient with suspected pulmonary hypertension (PH) presented 
to the hospital, a series of investigations was performed to con-
firm the diagnosis, determine the World Health Organization 
(WHO) group, and evaluate the functional and hemodynamic 
impairment. According to the update guidelines (7), PAH or 
Group 1 PH was defined as a mean pulmonary artery pressure 
(PAP) > 25 mmHg and a mean pulmonary capillary wedge pres-
sure (PCWP) < 15 mmHg by right heart catheterization (RHC). 
When RHC could not be performed, Doppler echocardiogra-
phy was used to confirm the diagnosis. The diagnostic criteria 
by Doppler echocardiography were as follows: pulmonary ar-
tery systolic pressure (PASP) > 40 mmHg calculated using a 
maximal systolic velocity (Vmax) of tricuspid regurgitation (TR) 
jet; mean PAP > 25 mmHg calculated based on the accelera-
tion time of the pulse Doppler spectral wave (PW) on the right 
ventricular outflow track (RVOT); and normal LV systolic and 
diastolic function and normal left arterial (LA) volume.
 When the patients were confirmed to have PAH, a specific 
etiology of PAH was also determined by well-established algo-
rithms (7). Patients with Group 2 PH (PH owing to left heart dis-
eases), Group 3 PH (PH owing to lung diseases), Group 4 PH (PH 
owing to chronic pulmonary thromboembolism), and Group 5 
PH (PH with unclear multifactorial mechanisms), as well as those 
who refused to be included, were excluded from the registry. 
Data collection
When a patient was diagnosed and agreed to be included in the 
study, all of the patient data were input by individual investiga-
tors into the webserver (http://www.korpah.or.kr). The follow-
ing baseline demographics were collected: age at diagnosis, 
gender, specific etiology of PAH, past medical history, date of 
confirmation, blood pressure, WHO functional class, electro-
cardiography, chest radiography, laboratory examinations (in-
cluding serum brain natriuretic peptide [BNP, pg/mL) or N-ter-
minal proBNP [NT-proBNP, pg/mL]), pulmonary function test 
results (including diffusion capacity for carbon monoxide [DLCO]), 
6-min walking distance (6MWD, meters), comorbid conditions 
and treatment modalities. RHC parameters were also collected, 
including mean pulmonary artery pressure (mPAP, mmHg), mean 
pulmonary capillary wedge pressure (mPCWP, mmHg), mean 
right arterial pressure (mRAP, mmHg), pulmonary vascular re-
sistance index (PVRI, Wood U*m2), cardiac index (CI, L/min*m2), 
and mixed venous oxygen saturation (SvO2, %). 
 Doppler echocardiographic indices such as peak tricuspid 
regurgitation velocity (TR Vmax, m/sec) of the tricuspid annu-
lus, time velocity integral (TVI, cm) and acceleration time (msec) 
of the pulse wave spectral wave signal of the right ventricular 
outflow track were measured. From these Doppler data, pul-
monary artery systolic pressure (PASP, mmHg), mean pulmo-
nary artery pressure (mPAP, mmHg) and pulmonary vascular 
resistance (PVR, WU) were derived. Inferior vena cava (IVC) di-
ameter with/without respiratory variation, pericardial effusion 
and tricuspid annular plane systolic excursion (TAPSE, mm) 
were also recorded. Follow-up clinical data and Doppler echo-
cardiographic data were regularly recorded in every 6-12 months. 
When a clinical event (death or re-hospitalization) occurred, the 
date and cause of the event were updated on the webserver. 
Statistical analysis 
To describe the baseline characteristics and co-morbid condi-
tions of all the KORPAH patients and incident PAH cases, we used 
frequency (proportion) for categorical variables and means ±  
standard deviations for continuous variables. The denominator 
for proportion was based on the number of patients with com-
plete data. To compare baseline characteristics according to sub-
groups of PAH (idiopathic pulmonary arterial hypertension 
[IPAH] or acquired pulmonary arterial hypertension [APAH]) 
and WHO functional classes (less than class II or more than class 
III) in the KORPAH patients, we used the independent t-test or 
Wilcoxon rank sum test for continuous variables and the chi-
square test for categorical variables. In the KORPAH patients 
diagnosed by RHC, diagnostic RHC parameters such as mPAP, 
PCWP, mRAP, PVRI, and SvO2 were compared between IPAH 
and APAH patients using the independent t-test. Survival rates 
from enrollment among newly diagnosed PAH patients were 
calculated using the life-table method. We conducted log-rank 
tests to compare survival rates according to PAH subgroups 
(IPAH, congenital heart disease [CHD], and connective tissue 
disease [CTD]). To assess the factors associated with mortality 
among newly diagnosed PAH patients, hazard ratios and 95% 
confidence intervals were calculated using the Cox’s propor-
tional hazard model. Univariate analysis was conducted, and 
the multivariate Cox’s proportional hazard model was used to 
adjust for confounding variables. We used SAS 9.3.1 (SAS Insti-
tute, Cary, NC, USA) for all statistical analyses, and P values less 
than 0.05 were considered significant. 
Ethics statements
The protocol of the KORPAH was reviewed and approved by the 
institutional review board of each participating hospital (hospi-
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tal of corresponding author: KC13RIMI0384). The need for in-
formed consent was exempted by the board. Audit processes 
were performed by an independent investigator to validate the 
diagnosis of PAH and the precision of the data.
RESULTS
Demographics and baseline characteristics of all patients 
From September 2008 to December 2011, a total of 625 consec-
utive patients with WHO group 1 PH or PAH were enrolled in 
the registry. In total, 249 (39.8%) patients met the study entry 
criteria of RHC, and 376 (60.2%) patients met those of Echo. The 
baseline characteristics and comorbid conditions of all patients 
and their respective percentages according to the specific etiol-
ogies are summarized in Table 1. Of all 625 patients, the mean 
age at enrollment was 47.6 ± 15.7 yr. In total, 112 patients (17.9%) 
were older than 65 yr, and there were 503 female patients (80.5%). 
The most common etiology of PAH was CTD (n = 311, 49.8%), 
followed by CHD (n = 159, 25.4%) and IPAH (n = 145, 23.2%). 
Approximately 19.4% of patients had essential hypertension, 
8.2% had diabetes, 15.3% were obese and only 4.2% were cur-
rent smokers. WHO functional classes II, III, and IV correspond-
ed to 218 (34.9%), 240 (38.4%), and 31 patients (5.0%), respec-
tively. Systolic blood pressure, BNP or NT-proBNP, and 6-min 
walking distances were not significantly different between the 
IPAH and APAH patients. However, DLCO was significantly lower 
in APAH patients (P = 0.001). Table 2 presents the characteristics 
according to the WHO functional class at enrollment. IPAH pati-
ents exhibited a more severe functional class than other subty pes, 
whereas CTD patients exhibited a less severe functional class 
(P < 0.001). There were significant differences in 6MWD or NT-
proBNP between functional classes I/II and III/IV (P < 0.001). 
Table 1. Baseline characteristics and comorbid conditions of KORPAH patients 
Parameters All patients IPAH
All patients with 
APAH
P value
APAH subgroup
CHD CTD Other
Patients, No. (%) 625 (100) 145 (23.2) 480 (76.8) 159 (25.4) 311 (49.8) 10 (1.6)
Age, mean ± SD (yr) 47.6 ± 15.7 45.1 ± 15.7 48.4 ± 15.7 0.027 41.1 ± 13.4 52.2 ± 15.6 47.7 ± 10.0
   19-64, No. (%) 513 (82.1) 121 (83.5) 392 (81.7) NS 149 (93.7) 233 (74.9) 10 (100)
   65-74, No. (%) 74 (11.8) 18 (12.4) 56 (11.7) 8 (5.0) 48 (15.4) -
  > 75, No. (%) 38 (6.1) 6 (4.1) 32 (6.7) 2 (1.3) 30 (9.7) -
Female, No. (%) 503 (80.5) 106 (73.1) 397 (82.7) 0.011 116 (73.0) 274 (88.1) 7 (70.0)
Functional class, No. (%) < 0.001
   I 136 (21.8) 5 (3.5) 131 (27.3) 9 (5.7) 121 (38.9) 1 (10.0)
   II 218 (34.9) 48 (33.1) 170 (35.4) 71 (44.7) 96 (30.9) 3 (30.0)
   III 240 (38.4) 82 (56.6) 158 (32.9) 76 (47.8) 77 (24.8) 5 (50.0)
   IV 31 (5.0) 10 (6.9) 21 (4.4) 3 (1.9) 17 (5.5) 1 (10.0)
Comorbid conditions, No (%)
   Hypertension 102 (19.4) 21 (14.8) 81 (21.0) NS 5 (7.8) 75 (24.1) 1 (10.0)
   DM 43 (8.2) 8 (5.6) 35 (9.1) NS 6 (9.4) 28 (9.0) 1 (10.0)
   Obese (BMI ≥ 25) 71 (15.3) 18 (15.9) 53 (15.1) NS 9 (14.5) 39 (14.0) 5 (50.0)
   IHD 13 (2.5) 5 (3.5) 8 (2.1) NS 2 (3.1) 6 (1.9) -
   Renal failure 8 (2.9) 4 (2.8) 4 (3.0) NS - 3 (5.2) 1 (10.0)
   Liver cirrhosis 12 (2.3) 3 (2.1) 9 (2.3) NS - - 9 (90.0)
   Cancer 19 (3.6) 8 (5.6) 11 (2.9) NS 2 (3.1) 8 (2.6) 1 (10.0)
   Pulmonary tuberculosis 19 (3.6) 3 (2.1) 16 (4.2) NS 2 (3.1) 14 (4.5) -
   Chronic hepatitis 2 (0.4) - 2 (0.5) NS - 1 (0.3) 1 (10.0)
   Arrhythmia 3 (0.6) 2 (1.4) 1 (0.3) NS 1 (1.6) - -
   Asthma 1 (0.2) 1 (0.7) - NS - - -
   COPD  5 (1.0) 2 (1.4) 3 (0.8) NS - 3 (1.0) -
   Thyroid diseases 8 (1.5) 3 (2.1) 5 (1.3) NS - 5 (1.6) -
   TIA 5 (1.0) 2 (1.4) 3 (0.8) NS 1 (1.6) 2 (0.6) -
   Smoking 0.002
      Never 467 (89.1) 115 (82.1) 352 (91.7) 57 (90.5) 287 (92.3) 8 (80.0)
      Ex-smoker 35 (6.7) 18 (12.9) 17 (4.4) 3 (4.8) 13 (4.2) 1 (10.0)
      Current smoker 22 (4.2) 7 (5.0) 15 (3.9) 3 (4.8) 11 (3.5) 1 (10.0)
Systolic BP (mean ± SD) 114 ± 16.8 116 ±  17.6 113 ± 16.1 NS 113 ± 14.8 111 ± 18.3 118 ± 21.3
BNP (pg/mL) 516 ± 1,093 465 ± 1,001 562 ± 1,176 NS 645 ± 1,423 362 ± 444 871 ± 662
NT proBNP (pg/mL) 2,798 ± 6,375 2,192 ± 3,244 2,876 ±  6,673 NS 1,900 ± 5,047 3,234 ± 7,152 687 ± 978
6MWD (mean ± SD, m) 376 ± 124 398 ± 116 364 ± 127 NS 382 ± 119 347 ± 133 277 ± 162
DLCO (%) 64.1 ± 24.3 74.1 ± 20.7 59.3 ± 24.5* < 0.001 95.1 ± 34.5 56.3 ± 20.9 52.2 ± 22.5
P values for 6 MWD, SBP, BNP, NT proBNP, and DLCO were obtained from the independent t-test or Wilcoxon rank sum test to compare the means between functional classes I/II 
and III/IV. P values for categorical data were obtained from chi-square test or Fisher’s exact test. NS: P > 0.05. APAH, acquired pulmonary arterial hypertension; IPAH, idiopathic 
pulmonary arterial hypertension; CHD, congenital heart disease; CTD, connective tissue disease; DM, diabetes mellitus; IHD, ischemic heart disease; COPD, chronic obstructive 
lung disease; TIA, transient ischemic attack; BP, blood pressure; BNP, serum brain natriuretic peptide; NT-proBNP, serum N-terminal proBNP; 6MWD, 6-minute walking distance; 
DLCO, diffusion capacity for carbon monoxide.
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Functional class III or IV patients were more frequently treated 
by PAH-specific single or combination treatments. Conversely, 
functional class I or II patients were more frequently treated by 
conventional drugs such as diuretics and warfarin. 
 Of 625 patients, only 249 patients were diagnosed by RHC. As 
shown in Table 3, of these 249 patients, 34.9%, 43.0%, and 20.9% 
had IPAH, CHD, and CTD, respectively. These proportions were 
quite different than those of all patients (23.2%, 25.4%, and 49.8%, 
respectively). The comparisons of RHC parameters for the 249 
patients are presented in Table 3. There were no significant dif-
ferences in any parameters between patients with IPAH and 
those with APAH.
Characteristics of the incident cases 
Of all patients, 328 patients were enrolled at the beginning of 
registry (prevalent cases), and 297 patients were enrolled dur-
ing the study (incident cases). The specific etiology of PAH and 
the baseline characteristics of the 297 incident cases are present-
ed in Table 4. Of these 297 patients, CTD was the most common 
etiology (57.6%), followed by CHD (26.9%) and IPAH (12.5%). 
The mean age and the frequency of women among these pa-
tients were similar to those of all patients. Systolic blood pres-
sure, BNP or NT-proBNP, 6MWD and DLCO were not significant-
ly different between IPAH and APAH in the incident cases (Ta-
ble 4). According to the Korean Statistical Information Service 
in the year of 2010, the population was 47,990,761. Therefore, 
the incidence rate of PAH was 1.9 patients/yr/million people. At 
enrollment, 123 of 297 (41.0%) patients were functional class 
III, and 19 (6.0%) were functional class IV. IPAH patients exhib-
ited more severe functional classes than did other subtypes 
(Table 4). Among the 297 patients, only 106 patients were diag-
nosed by RHC. The comparisons of the RHC parameters in the 
106 patients are presented in Table 5. Among the incident cases 
diagnosed by RHC, CHD and CTD comprised 49.1% and 30.2%, 
respectively (Table 5). There were no significant differences in 
any of the RHC parameters between patients with IPAH and 
APAH. Table 6 presents the PAH-specific medications in all pa-
tients (n = 625) and incidence patients (n = 297) in the KOR-
Table 2. Comparisons according to WHO functional classes in KORPAH patients
Parameters
Class I, II  
(n = 354, 56.6%)
Class III, IV 
(n = 271, 43.4%)
P value
Age (yr)
  < 40
   40-49
   50-59
  ≥ 60
116
83
70
85
95
69
49
58
NS
Sex 
   Male
   Female
71
283
51
220
NS
Department
   Cardiology
   Pulmonology
   Rheumatology
   Pediatrics
60
51
199
44
72
91
54
54
< 0.001
Subtype
   IPAH
   CHD
   CTD
   Other
53
80
217
4
92
79
94
6
< 0.001
Time at diagnosis
   Before 2005. 8
   After 2005. 8
78
276
65
206
NS
Diagnosis method
   RHC
   Echo
122
232
127
144
0.002
Treatment
   No
   Conventional
   Single
      Bosentan
      Sildenafil
      Iloprost
      Beraprost
   Combination
58
122
146
58
29
9
50
28
25
45
162
97
16
13
36
44
< 0.001
6MWD (m)
  < 379
   380-439
  ≥ 440
26
20
42
66
24
25
< 0.001
BNP (pg/mL)
  < 174
  ≥ 174
26
20
33
32
NS
NT proBNP (pg/mL)
  < 797
  ≥ 797
104
53
40
66
< 0.001
P values for BNP and NT proBNP were obtained from the Wilcoxon rank sum test to 
compare the means between functional classes I/II and III/IV. NS: P > 0.05. Echo, 
Doppler echocardiography; RHC, right heart catheterization; 6MWD, 6 minutes Walk-
ing distances.
Table 3. Comparison of RHC parameters between IPAH and APAHs
Parameters All patients IPAH
All patients with 
APAH
P value
APAH subgroup
CHD CTD Other
Patients, No. (%) 249 87 (34.9) 162 (65.1) 107 (43) 52 (20.9) 3 (1.2)
RHC parameters 
mPAP (mmHg) 55.3 ± 17.3 57.7 ± 18.2 54.0 ± 16.7 NS 58.5 ± 16.1 44.4 ± 13.8 47.0 ± 17.0
mPCWP (mmHg) 8.18 ± 3.47 8.68 ± 3.18 7.66 ± 3.70 NS 6.97 ± 3.64 8.67 ± 3.34 9.33 ± 6.03
mRAP (mmHg) 8.92 ± 5.64 9.74 ± 6.75 8.51 ± 5.00 NS 7.80 ± 4.07 12.9 ± 8.10 10.0 ± 4.24
PVRI (Wood units·m2) 9.28 ± 5.84 8.40 ± 4.97 10.1 ± 6.55 NS 10.2 ± 7.18 9.41 ± 4.04 14.4 ± 17.4
CI (L/min·m2) 2.44 ± 0.77 2.43 ± 0.68 2.46 ± 0.92 NS 2.99 ± 1.03 2.17 ± 0.62 2.12 ± 1.33
SvO2 (%) 51.6 ± 21.0 52.4 ± 16.3 51.0 ± 24.4 NS 57.5 ± 28.9 45.1 ± 12.7 34.0 ± 8.72
NS: P > 0.05. APAH, acquired pulmonary arterial hypertension; IPAH, idiopathic pulmonary arterial hypertension; CHD, congenital heart disease; CTD, connective tissue disease; 
RHC, right heart catheterization; mPAP, mean pulmonary artery pressure; mPCWP, mean pulmonary capillary wedge pressure; mRAP, mean right arterial pressure; PVRI, pulmo-
nary vascular resistance index; CI, cardiac index; SvO2, mixed venous oxygen saturation. 
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Table 4. Baseline characteristics of incident cases in KORPAH
Parameters All patients IPAH
All patients with 
APAH
P value 
APAH subgroup
CHD CTD Other
Patients, No. (%) 297 (100) 37 (12.5) 260 (87.5) 80 (26.9) 171 (57.6) 9 (3.0)
Age, mean ± SD (yr) 50.0 ± 16.6 47.0 ± 16.6 50.5 ± 16.6 NS 43.2 ± 13.7 54.1 ± 17.0 46.3 ± 9.6
Female, No. (%) 233 (78) 27 (73) 206 (79) NS 54 (68) 146 (85) 6 (67)
Functional class, No. (%)
   I
   II
   III
   IV
58 (20)
97 (33)
123 (41)
19 (6)
1 (3)
8 (22)
25 (68)
3 (8)
57 (22)
89 (34)
98 (38)
16 (6)
0.002
3 (4)
33 (41)
43 (54)
1 (1)
53 (31)
54 (32)
50 (29)
14 (8)
1 (11)
2 (22)
5 (56)
1 (11)
Systolic BP (mean ± SD) 114 ± 16.5 113 ± 16.2 115 ± 16.7 NS 115 ± 16.0 112 ± 17.5 115 ± 20.8
BNP (pg/mL) 721 ± 1,619 749 ± 1,652 705 ± 1,632 NS 922 ± 2,117 305 ± 385 871 ± 662
NT proBNP (pg/mL) 3,173 ± 6,960 2,508 ± 3,890 3,247 ± 7,276 NS 2,203 ± 5,589 3,762 ± 7,878 787 ± 1,059
6MWD (mean ± SD, m) 363 ± 116 353 ± 124 365 ± 115 NS 378 ± 109 358 ± 114 237 ± 173
DLCO (%) 62.0 ± 26.3 70.6 ± 24.8 60.3 ± 26.4 NS 93.1 ± 33.9 56.7 ± 22.7 52.2 ± 22.5
P values for 6MWD, SBP, BNP, NT proBNP, and DLCO were obtained from the independent t-test to compare the means between patients diagnosed with IPAH and all patients 
with APAH. P values for categorical data were obtained from chi-square test or Fisher’s exact test. NS: P > 0.05. APAH, acquired pulmonary arterial hypertension; IPAH, idio-
pathic pulmonary arterial hypertension; CHD, congenital heart disease; CTD, connective tissue disease; BP, blood pressure; BNP, serum brain natriuretic peptide; NT-proBNP, 
serum N-terminal proBNP; 6MWD, 6-minute walking distance; DLCO, diffusion capacity for carbon monoxide.
Table 5. Comparisons of RHC parameters between IPAH and APAH in the incident cases of KORPAH
Parameters All patients IPAH
All patients  
with APAH
P value 
APAH subgroup
CHD CTD Other
Patients, No. (%) 106 19 (17.9) 87 (82.1) 52 (49.1) 32 (30.2) 3 (2.8)
RHC parameters
mPAP (mmHg) 51.9 ± 16.3 47.8 ± 11.3 52.8 ± 17.2 0.249 56.5 ± 17.3 46.5 ± 15.5 47.0 ± 17.0
mPCWP (mmHg) 7.36 ± 3.53 6.63 ± 3.12 7.68 ± 3.70 0.346 6.67 ± 3.10 9.30 ± 3.80 9.33 ± 6.03
mRAP (mmHg) 8.19 ± 4.18 6.57 ± 4.38 8.71 ± 4.02 0.096 8.66 ± 4.13 8.60 ± 3.97 10.0 ± 4.24
PVRI (Wood units·m2) 10.2 ± 6.38 8.91 ± 4.62 10.7 ± 7.03 0.652 10.6 ± 7.32 10.0 ± 4.56 14.4 ± 17.4
CI (L/min·m2) 2.35 ± 0.79 2.20 ± 0.44 2.44 ± 0.93 0.673 2.79 ± 1.00 2.19 ± 0.71 2.12 ± 1.33
SvO2 (%) 51.4 ± 22.0 51.0 ± 15.3 51.5 ± 25.3 0.628 57.5 ± 28.9 45.4 ± 15.5 34.0 ± 8.72
APAH, acquired pulmonary arterial hypertension; IPAH, idiopathic pulmonary arterial hypertension; CHD, congenital heart disease; CTD, connective tissue disease; RHC, right 
heart catheterization; mPAP, mean pulmonary artery pressure; mPCWP, mean pulmonary capillary wedge pressure; mRAP, mean right arterial pressure; PVRI, pulmonary vascu-
lar resistance index; CI, cardiac index; SvO2, mixed venous oxygen saturation. 
Table 6. PAH-specific medications of KORPAH in all patients and incident patients
Medications Treatments in all patients (n = 625) Treatments in incidence cases (n = 297)
No. (%) of patients receiving PAH-specific medications in all treatments 380 (60.8) 182 (61.3)
No. (%) of medications in all PAH-specific treatments  
   Single bosentan 
   Single sildenafil  
   Single inhaled iloprost
   Single beraprost
   Combinations of above single medications
155 (40.9)
45 (11.8)
22 (5.8)
86 (22.6)
72 (18.9)
93 (51.1)
21 (11.6)
17 (9.3)
23 (12.6)
28 (15.4)
PAH. Among the 297 incidence patients, 182 (61.3%) patients 
were treated by PAH-specific medical therapies. Of those, 154 
(84.6%) patients received single medications; 93 were on bosen-
tan, 23 were on beraprost, 21 were on sildenafil, and 17 were on 
inhaled iloprost. Twenty-eight (15.4%) patients received com-
bination therapy. 
Prognosis of incident cases 
Of all 297 incidence cases, there were 35 cases of mortality dur-
ing the mean 1.7 yr of follow-up. The estimated mortality rate 
was 7/100 person-years. The cumulative survival curve of inci-
dent cases is presented in Fig. 1. The 1st-, 2nd-, and 3rd-year es-
timated survival rates were 90.8%, 87.8%, and 84.4%, respec-
tively. Fig. 2 presents the comparison of prognosis according to 
the etiologies of PAH. PAH with CTD corresponded to the high-
est mortality (18.8%), followed by IPAH (8.1%) and CHD (3.9%) 
(P = 0.043). 
DISCUSSION 
The present study is the first report of the clinical characteristics 
and epidemiology of Korean PAH patients as well as the first 
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PAH nationwide registry data in Asian counties. The important 
findings of the KORPAH were as follows: 1) the most common 
etiology of PAH was CTD, followed by CHD and IPAH in inci-
dence cases as well as in all patients; 2) middle-aged females 
were the most common subgroup of patients (80.5%); 3) approx-
imately 43.4% of patients had WHO class III or IV disease at di-
agnosis; 4) patients concurrently had essential hypertension 
(19.4%); diabetes (8.2%) and obesity (15.3%); 5) the incidence 
rate of PAH was 1.9 patients/yr/million people; 6) the estimated 
mortality rate was 7/100 person-years, and CTD-associated 
PAH (CTD-PAH) exhibited the worst prognosis (18.8%); 7) the 
incidence of systemic lupus erythematosus (SLE) (35.3%) was 
comparable to that of systemic sclerosis (SSc) (28.3%) in CTD-
PAH; 8) the 1st-, 2nd-, and 3rd-yr estimated survival rates were 
90.8%, 87.8%, and 84.4%, respectively.
 Previous large national observational registries have provid-
ed information on current PAH epidemiology, increasing aware-
ness about the disease (6, 8-11). However, most of the current 
data come from Western countries, and the few reports from 
PAH registries from Asian countries are limited to single referral 
center registries or registries from a single country (12, 13). One 
previous report from a Chinese registry included only IPAH and 
familial PAH patients who had not taken PAH-targeted drugs 
and were much younger than those included in western regis-
tries (12). The demographics of the KORPAH registry participants 
were similar to those of western registry participants (Table 7). 
The observed mean age (47.6 yr old) and female proportion of 
patients (80.5%) in the KORPAH more closely resembled those 
observed in the REVEAL registry (50.1 yr old and 79.5%, respec-
tively) than those in the Chinese registry (35.9 yr old and 70.8%, 
respectively). The KORPAH and other contemporary registries, 
including the REVEAL registry, indicate a similar shift in the age 
demographic to an older age at diagnosis and a greater female 
predominance since the time of the NIH registry (5, 6, 8-16).
 Recently, the Registry of Pulmonary Hypertension Associat-
ed with Rheumatic Disease (REOPARD), a nationwide, multi-
center, observational Korean registry, reported that Korean CTD-
PAH patents exhibit some differences with respect to underly-
ing diseases, functional status and treatment compared with 
western country registries (17, 18). However, this survey includ-
ed only CTD-PAH diagnosed by rheumatologists and exhibited 
some limitations (17). Therefore, the KORPAH may be an im-
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Fig. 1. Cumulative survival curve of the incident cases in the KORPAH (n = 297). The 
first-, second- and third-year estimated survival rates were 90.8%, 87.8%, and 
84.4%, respectively. 
Fig. 2. Comparison of survival according to the etiologies of PAH of the incident cas-
es in the KORPAH (n = 297). This figure presents a comparison of prognoses accord-
ing to the etiologies of PAH. PAH with CTD corresponded to the highest mortality (18.8%), 
followed by idiopathic PAH (IPAH) (8.1%) and PAH with congenital heart disease CHD 
(3.9%) (P = 0.043). CHD, congenital heart disease; CTD, connective tissue disease.
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Table 7. Comparisons of demographic, clinical and hemodynamic characteristics in world registries of PAH
Parameters REVEAL 2010 French 2006 Spain 2012 China 2011 Korea 2011
Cases (No) 2,525 674 866 956 625
Mean age (yr) 50 ± 14 50 ± 15 45 ± 17 36 ± 13 48 ± 16
Female (%)      80   65   71   70 80.5
WHO III/IV (%)      56   75   69   54 48.7
6MWD (m) 366 ± 126 329 ± 112 382 ± 117 353 ± 127 372 ± 123
mPAP (mmHg) 51 ± 14 55 ± 15 54 ± 16 63 ± 15 66 ± 22
PVRI (Wood U*m²) 21 ± 13 21 ± 10 NA 25 ± 14 10 ± 6
6MWD, 6-minute walking distance; mPAP, mean pulmonary artery pressure; PVRI, pulmonary vascular resistance index.
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portant and valuable registry because it explores the epidemio-
logical and clinical characteristics of Korean PAH patients for 
the first time. 
 Compared with previous registries, the most striking differ-
ence and limitation in the KORPAH was the performance rate 
of RHC. Among 625 patients, only 249 patients were diagnosed 
by RHC. RHC was performed in 60% of IPAH patients, 67% of 
CHD-PAH patients and 17% of CTD-PAH patients. Another dif-
ference between the KORPAH and other studies was the higher 
proportion of CTD-PAH patients (49.8%) relative to other regis-
tries. In the French and REVEAL registries, approximately half 
of the patients exhibited idiopathic disease, whereas the other 
half exhibited APAH (8-11). 
 Meta-analyses reveal that patients with CTD-PAH exhibit 
more severe symptoms and worse prognoses compared with 
other etiologies of PAH (18, 19). Although CTD-PAH patients in 
the KORPAH exhibited the worst prognoses, there were some 
differences relative to other registries. With respect to function-
al class, CTD-PAH in the KORPAH corresponded to a remark-
ably higher proportion of WHO functional class I and II (63%) 
patients than did IPAH in the KORPAH, which differed signifi-
cantly from the results of other registries (12%-28%). This dis-
crepancy may be partly due to the diagnostic tool used in this 
study. Most CTD-PAH patients in the KORPAH were diagnosed 
only with Doppler echocardiography and clinical histories, sug-
gesting that many rheumatology doctors may have included 
PAH patients without confirmation of RHC (17). This fact may 
have contributed to the relatively higher proportion of CTD-PAH 
patients, an overestimation of mPAP, and a higher proportion of 
patients with less severe disease in the KORPAH. 
 In previous studies, patients with CTD-PAH exhibited worse 
DLCO, had higher BNP levels, and performed more poorly on 
the 6MWD test compared with patients with PAH due to other 
causes (18, 19). However, in this study, these parameters did not 
differ significantly between CTD-PAH patients and IPAH pa-
tients. With respect to the survival rate, worse prognostic factors 
failed to exhibit significant differences between patients with 
CTD-PAH and IPAH, and CTD-PAH patients exhibited the worst 
1-yr survival rate (81.2%). However, this result was better than 
those reported from other large registries. The 1- and 3-yr sur-
vival rates were 78% and 47% in SSc-PAH patients, respectively, 
and 78% and 74% in SLE-PAH patients, respectively, in a UK 
registry (15); the one-year survival rate of CTD-PAH was 86% in 
the REVEAL registry (8-10). A recent cohort study from China 
(12) indicated that the 1- and 3-yr survival rates of CTD-PAH 
patients are 85.4% and 53.6%, respectively. The superior surviv-
al outcomes of our registry may be the result of employing pa-
tients with less severe disease or attributed to ethnic differences.
 Finally, with respect to the subgroups of CTD-PAH, the most 
common underlying diseases associated with CTD-PAH in pre-
vious studies were reported to be systemic sclerosis, followed 
by SLE and mixed connective tissue disease; most of these stud-
ies were conducted in western countries (18, 19). In contrast, 
the frequency of SLE as the underlying CTD was higher than 
that of systemic sclerosis in our study (35.3% vs. 28.3%). This 
pattern was also noted in other studies conducted in Japan (20), 
China (13), and the Philippines (21). This discrepancy of under-
lying diseases may also result from differences in environment 
and ethnicity. 
 With respect to hemodynamic data from RHC in the KOR-
PAH, CTD-PAH patients exhibited no significant differences in 
important parameters such as mPAP, PCWP, or RVSP relative to 
IPAH patients. Furthermore, the mPAP values of the IPAH pa-
tients who underwent RHC in the KORPAH were similar to the 
values in the IPAH patients in the REVEAL and French regis-
tries but were slightly lower than a single center cohort of IPAH 
patients in Korea (57.7 mmHg, 52.1 mmHg, 55 mmHg, and 61 
mmHg, respectively) (8-11, 22). 
 Approximately 43% of patients in the KORPAH had WHO class 
III or IV disease at diagnosis which was quite similar to a previ-
ously reported single center cohort in Korea (40%) (23), suggest-
ing that PAH continues to be detected at an advanced stage of the 
disease. In addition to the under-utilization of RHC for the con-
firmation of PAH, the KORPAH reveals that PAH-targeted drugs 
are under-prescribed (approximately 61%). Only 380 (60.8%) 
patients received a single PAH-specific treatment at the time of 
enrollment, and only 72 (18.9%) patients received combination 
therapy. The reasons for this late detection and under-treatment 
might be due to insufficient awareness of the disease in Korea. 
Thus, continued efforts to increase awareness among the pub-
lic and clinicians should be warranted for the early detection 
and optimal management of PAH patients. 
 The KORPAH was a national observational and voluntary re-
gistry that was created by 4 Korean academic societies. There-
fore, the web design of the registry and its tone varied among 
participating academic societies, and the completeness of data 
entered into the registry varied. However, we nonetheless be-
lieve that a nationwide, multicenter registry is necessary for a 
rare disease like PAH. McLaughlin and Suissa (24) described 
the importance and limitations of nationwide registries as fol-
lows: “To further our comprehension of rare diseases, we often 
turn to registries constructed as multicenter cohorts of patients 
who have the disease with longitudinal follow-up. Despite the 
inherent limitations of their observational and uncontrolled 
nature, which also represent strengths, these cohorts are useful 
to describe and compare patient characteristics, practice pat-
terns, and outcomes.” To maintain the quality and precision of 
the KORPAH data, multiple audit processes should be under-
taken by an independent investigator.
 In conclusion, we report the clinical data of all 625 patients 
and 297 incidence patients with PAH in Korea in this article. Com-
pared with western registries, Korean PAH patients exhibited 
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similar age, gender and survival rate. However, in the etiology, 
KORPAH and Chinese registry show more CTD-PAH and SLE 
among them than western registries, which may be related to 
ethnic difference. Also, as showed in other world registries, the 
results of KORPAH suggest that earlier standardized diagnosis 
and more specialized medical therapies should be needed to 
improve the survival of PAH patients in Korea. Finally, observa-
tions from the KORPAH should generate hypotheses that will 
prompt future subsequent studies.
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